Health
FDA Panel Reviews Peptide Compounding
An FDA panel recommended allowing compounding pharmacies to produce two more peptides, a step toward making them more widely available. The decision comes as the FDA questions the efficacy of Capricor’s Duchenne drug.
Coverage timeline — 2 articles
STAT News
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
2026-07-27 13:08 UTC
STAT News
An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more available
2026-07-27 13:19 UTC